MHLW Designates Biogen Idec’s MS Drug Natalizumab Orphan Drug
This article was originally published in PharmAsia News
The first session of Japan's Ministry of Health, Labor and Welfare's drug review board designated Biogen Idec's natalizumab an orphan drug April 25. Marketed under Tysabri, natalizumab is approved in the United States for treating relapsing forms of multiple sclerosis, and in the European Union for relapsing-remitting forms of MS. Biogen Idec Japan, the American company's Japanese subsidiary plans to start clinical trials in Japan soon. (Click here for more - Japanese language)
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.